Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:35:04 2024-02-23 am EST 5-day change 1st Jan Change
2.546 EUR -0.62% Intraday chart for Cellectis S.A. -0.93% -7.89%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
AstraZeneca: $300 million invested in the USA CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6% MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Cellectis: second tranche of EIB loan drawn down CF
Cellectis Draws Down EUR15 Million Tranche Under European Investment Bank Credit Facility MT
Cellectis Announces the Drawdown of the Second Tranche of 15 Million Under the Credit Facility Agreement Entered with the European Investment Bank CI
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week on Positive Note in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Edge Higher Friday MT
Cellectis S.A. Announces Board Appointments CI
European Equities Traded in the US as American Depositary Receipts Gain Thursday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But Close Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesday MT
European Equities Traded in the US as American Depositary Receipts Move Slightly Lower Tuesday MT
European Equities Traded in the US as American Depositary Receipts Climb Higher Friday MT
European Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply Friday, Up 2.7% for Week MT
European Equities Traded in the US as American Depositary Receipts Steady in Thursday Trading MT
Chart Cellectis S.A.
More charts
Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Cellectis S.A. - Euronext Paris
  4. News Cellectis S.A.
  5. European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer